O'Dwyer ME, Swords R, Nagler A, McMullin MF, le Coutre PD, Langabeer SE, Alvarez-Iglesias A, Fan H, Woodman RC, Giles FJ, Conneally E. Nilotinib 300mg BID as frontline treatment of CML: Prospoective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response. Leuk Res. 2014 Mar;38(3):310-5
Giles FJ, Krawczyk J, O'Dwyer M, Swords R, Freeman C. The role of inflammation in leukaemia. Adv Exp Med Biol. 2014;816:335-60
Stein BL, Swords R, Hochhaus A, Giles F. Novel myelofibrosis treatment strategies: potential partners for combination therapies. Leukemia. 2014 Jun 3, Epub ahead of print.